In global health research, is it legitimate to stop clinical trials early on account of their opportunity costs?

PLoS Medicine

Volumn 6, Issue 6, 2009, Pages

  Lavery, James V ^a,b,c   Singer, Peter A ^c   Ridzon, Renee ^d   Singh, Jerome A ^b,c,e   Slutsky, Arthur S ^b,f   Anisko, Joseph J ^g   Buchanan, David ^h  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d BILL AND MELINDA GATES FOUNDATION   (United States)

^e UNIVERSITY OF KWAZULU NATAL   (South Africa)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g NONE

^h UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST BENEFIT ANALYSIS; DECISION MAKING; GLOBAL CHANGE; HEALTH CARE PLANNING; HEALTH INSURANCE; MEDICAL TECHNOLOGY; REVIEW;

ANTI-INFECTIVE AGENTS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; DRUGS, INVESTIGATIONAL; HUMANS; RESEARCH DESIGN; RESEARCH SUBJECTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 67650217955     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1000071     Document Type: Review

References (22)

1. [No authors listed] (2007) Trial and failure. Nature 446: 1.
2. Gross M (2004) HIV topical microbicides: Steer the ship or run aground. Am J Pub Health 94:1085-1089.
3. Harrison PF (2003) By way of introduction. Microbicide Quarterly 1: 1-4. Available: http://www.microbicide.org/galleries/tmq/tmq-apr- jun2003-final.pdf. Accessed 27 April 2009.
4. Forum for Collaborative HIV Research (2007) A new era for HIV prevention? Report of the Forum for Collaborative HIV Research Biomedical Interventions of HIV Prevention Working Group September 2006 Meeting. Washington D.C.: Department of Prevention and Community Health, The George Washington University School of Public Health and Health Services. Available: http://www.hivforum.org/ storage/hivforum/documents/FINAL%20REPORT%20ML%20020907.pdf. Accessed 27 April 2009.
5. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, et al. (2004) Efficacy of the RTS, S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: Randomized controlled trial. Lancet 364:1411-1420.
6. Aponte JJ, Aide P, Renom M, Mandomando I, Bassat Q, et al. (2007) Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: A double blind randomized controlled phase I/IIb trial. Lancet 370: 1523-1524.
7. Hill AV (2006) Pre-erythrocytic malaria vaccines: Towards greater efficacy. Nat Rev Immun 6:21-32.
8. Mullen GED, Ellis RD, Miura K, Malkin E, Nolan C, et al. (2008) Phase 1 trial of AMA1-C1/ Alhydrogel plus CPG 7909: An asexual blood-stage vaccine for Plasmodium falciparum malaria. PLoS ONE 3: e2940. doi:10.1371/journal. pone.0002940.
9. PATH (2008) $48 billion global AIDS plan becomes law: New PEPFAR bill boosts lifesaving services, encourages support for research and development. Available: http://www.path.org/news/an080730-pepfar.php. Accessed 27 April 2009 July 30.
10. Berndt ER, Hurvitz JA (2005) Vaccine advance-purchase agreements for low-income countries: Practical issues. Health Aff 24: 653-665.
11. Dickerson K, Rennie D (2003) Registering clinical trials. JAMA 290: 516-523
12. Slutsky AS, Lavery JV (2004) Data safety and monitoring boards. N Engl J Med 350:1143-1147.
13. Martin DK, Singer PA (2007) Priority setting. In: Singer PA, Viens A, eds. Bioethics for clinicians. Cambridge: Cambridge University Press.
14. Daniels N (2000) Accountability for reasonableness. BMJ 321: 1300-1301.
15. Daniels N, Sabin JE (1997) Limits to health care: Fair procedures, democratic deliberation and the legitimacy problem for insurers. Philos Public Aff 26: 303-350.
16. Daniels N, Sabin JE (2002) Setting limits fairly: Can we learn to share medical resources? Oxford: Oxford University Press. 208 p.
17. Cohen J (1994) Pluralism and proceduralism. Chicago-Kent Law Review 69: 589-618.
18. Rawls J (1993) Political liberalism. New York: Columbia University Press. 576 p.
19. DAMOCLESE Study Group (2005) A proposed charter for clinical trial data monitoring committees: Helping them to do their job well. Lancet 365: 711-722.
20. Upshur REG (2001) The ethics of alpha: Reflections on statistics, evidence and values in medicine. Theor Med Bioeth 22: 565-576.
21. Dresser R (2001) When science offers salvation: Patient advocacy and research ethics. New York: Oxford University Press. 232 p.
22. HIV Prevention Trials Network (2008) HPTN 035 PRO 2000 gel trial announcement. Available: http://www.hptn.org/research-studies/HPTN035.asp. Accessed 27 April 2009.